SWAP: Adding or Switching to PegIFN Improves Response in Patients With Chronic Hepatitis B on Long-Term NA Therapy

November 8-12, 2019; Boston, Massachusetts
Patients on stable nucleos(t)ide analogue therapy who added or switched to pegIFN had significantly better HBeAg loss rates and HBsAg level reductions compared with patients who continued nucleos(t)ide analogue therapy alone.
Format: Microsoft PowerPoint (.ppt)
File Size: 186 KB
Released: November 16, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.

Related Content

Takeshi Saito, MD, PhD, discusses the limitations of current approaches to treating HDV and looks ahead to new and emerging HDV therapies, from Clinical Care Options (CCO)

Takeshi Saito, MD, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 28, 2021 Expired: September 27, 2022

Download key slides describing lessons learned in delivery of care from the COVID-19 pandemic worth carrying forward in the management of viral hepatitis.

Gregory Dore, MBBS, PhD, FRACP, MPH Stacey Trooskin, MD, PhD, MPH Released: September 23, 2021

Brief Clinical Care Options (CCO) presentation on using the EASL guidelines to determine treatment candidacy in patients with hepatitis B virus HBV.

Maria Buti, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 7, 2021 Expired: September 6, 2022

Clinical Care Options (CCO) expert commentary from Maria Buti, MD, on her approach to assessing patients with HBV for treatment candidacy in the setting of other host factors.

Maria Buti, MD Released: August 26, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue